Cara Therapeutics(CARA) - 2024 Q1 - Quarterly Report

● the length of time required to enroll eligible patients; ● the number of doses that patients receive; ● the drop-out or discontinuation rates of patients; ● potential additional safety monitoring or other studies requested by regulatory agencies; ● the duration of patient follow-up; and ● the efficacy and safety profile of the product candidate. injection commenced on April 1, 2024. The unfavorable CMS reimbursement codified in the final CY2024 4l Table of Contents In addition, the probability of success ...